4 Companies Leading the Next Wave of Cancer-Drug Innovation
First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover.
Matt Coffina: For Morningstar StockInvestor, I'm Matt Coffina. I am joined today by Damien Conover, who is the director of our health-care team. We are going to talk about immuno-oncology drugs.
Damien, thanks for joining me.
Matthew Coffina does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.